Summary:
The primary objective of the study is to evaluate the efficacy of monthly doses of aducanumab in slowing cognitive and functional impairment.
Qualified Participants Must:
Be between 50 and 85 years of age
Have availability of a study partner
Have memory loss
Qualified Participants May Receive:
Compensation for time and travel.